Yong Yu - 01 Sep 2025 Form 4 Insider Report for GENELUX Corp (GNLX)

Role: SVP, Clinical Development
Signature: /s/ Thomas Zindrick, J.D. Attorney-in-Fact
Issuer symbol: GNLX
Transactions as of: 01 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Sep 2025, 16:15:33 UTC
Previous filing: 29 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yu Yong	SVP, Clinical Development	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE	/s/ Thomas Zindrick, J.D. Attorney-in-Fact	03 Sep 2025	0001937482

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GNLX	Stock Option (Right to Buy)	Disposed to Issuer		-207,652	-100%		0	01 Sep 2025	Common stock	207,652	$6.00	Direct	F1, F2
transaction	GNLX	Stock Option (Right to Buy)	Award		+207,652			207,652	01 Sep 2025	Common stock	207,652	$3.33	Direct	F1, F2
transaction	GNLX	Stock Option (Right to Buy)	Disposed to Issuer		-65,000	-100%		0	01 Sep 2025	Common stock	65,000	$22.40	Direct	F2, F3
transaction	GNLX	Stock Option (Right to Buy)	Award		+65,000			65,000	01 Sep 2025	Common stock	65,000	$3.33	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option are fully vested.
F2	The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.
F3	The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.